Changes in the Board of Directors and the Corporate Executive Committee of Roche - Seite 2
Change in the Corporate Executive Committee
Dr Gottlieb A. Keller (65), General Counsel, member of the Corporate Executive Committee, and Secretary to the Board of Directors, will retire at the end of March 2020. The Board of Directors has appointed Claudia Böckstiegel (55), currently Head of Legal of the Diagnostics Division, to the position of General Counsel, and she will become a member of the Enlarged Corporate Executive Committee as of 1 April 2020.
Severin Schwan, CEO of Roche: "I would like to thank Gottlieb Keller most sincerely for his many contributions during his 35-year career at Roche. Gottlieb Keller is an outstanding lawyer and at the same time a strong leader with a comprehensive understanding of our industry. I wish him all the best for the future. I am delighted that Claudia Böckstiegel, a very competent and experienced successor from our own ranks, will take on the role of General Counsel".
Anzeige
Dr Annette Luther (49), currently General Manager of Roche Diagnostics International AG in Rotkreuz, will succeed Dr Gottlieb Keller as Secretary to the Board of Directors.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
3 im Artikel enthaltene WerteIm Artikel enthaltene Werte